Agenus Inc
Agenus Inc (AGEN) Covered Calls
Agenus Inc trades in the Biotechnology industry with an IV Rank of 4.76%, low versus the past year. AGEN's highest covered call setup is the $17.00 strike expiring May 21, 2027, sorted by theoretical annualized return. It's 176.87% out of the money with 183 days to expiration, a 177.69% return until expiration, and a 354.40% theoretical annualized return. Across the setups shown, annualized returns run from 100.12% to 354.40% at strikes between $7.00 and $17.00, with 29 to 428 days to expiration, as of Nov 19, 2026.
Read more
Running AGEN covered calls helps you generate income from Agenus Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best AGEN covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If AGEN stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling AGEN covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given AGEN covered call is worth writing.
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody.
| 2027-05-21 | 183 | 17.00 | 176.87 | 0.05 | 0.50 | 1091.00 | 177.69 | 354.40 | -0.81 | +0.16 | 0 | 0.45 |
| 2027-02-19 | 92 | 10.00 | 62.87 | 0.10 | 0.80 | 396.00 | 64.50 | 255.88 | -1.63 | +0.28 | 205 | 0.70 |
| 2026-12-18 | 29 | 7.00 | 14.01 | 0.10 | 0.65 | 96.00 | 15.64 | 196.79 | -1.63 | +0.37 | 25 | 0.55 |
| 2027-05-21 | 183 | 11.00 | 79.15 | 0.05 | 0.85 | 491.00 | 79.97 | 159.50 | -0.81 | +0.26 | 0 | 0.80 |
| 2028-01-21 | 428 | 17.00 | 176.87 | 0.10 | 3.50 | 1096.00 | 178.50 | 152.23 | -1.63 | +0.51 | 2 | 3.40 |
| 2027-05-21 | 183 | 10.00 | 62.87 | 0.05 | 1.75 | 391.00 | 63.68 | 127.01 | -0.81 | +0.40 | 109 | 1.70 |
| 2028-01-21 | 428 | 15.00 | 144.30 | 0.20 | 2.30 | 906.00 | 147.56 | 125.84 | -3.26 | +0.42 | 673 | 2.10 |
| 2027-02-19 | 92 | 8.00 | 30.29 | 0.05 | 1.15 | 191.00 | 31.11 | 123.42 | -0.81 | +0.38 | 2 | 1.10 |
| 2027-05-21 | 183 | 9.00 | 46.58 | 0.30 | 1.70 | 316.00 | 51.47 | 102.65 | -4.89 | +0.44 | 10 | 1.40 |
| 2027-01-15 | 57 | 7.00 | 14.01 | 0.10 | 0.95 | 96.00 | 15.64 | 100.12 | -1.63 | +0.42 | 360 | 0.85 |
As of Nov 19, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank4.76% Low
- Market cap (M$)270
- 52 weeks high-42.10%
- 52 weeks low120.30%
- Analyst recommendationStrong Buy
1.00 - Target price$25.00
318.76% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-05
- P/E8.23
- Future P/E—
- EPS (ttm)0.73
- EPS growth next 5 years32.16%
As of Nov 20, 2026